<DOC>
	<DOCNO>NCT00109356</DOCNO>
	<brief_summary>The purpose study find answer follow question : - What large dose AQ4N give safely one time every three week 24 week ? - What side effect AQ4N give accord schedule ? - How much AQ4N blood certain time administration body get rid drug ? - Will AQ4N help treat lymphoid cancer ?</brief_summary>
	<brief_title>Study AQ4N Patients With Non Hodgkin 's Lymphoma , Chronic Lymphocytic Leukemia , Small Lymphocytic Leukemia</brief_title>
	<detailed_description>All patient study receive AQ4N one time every three week maximum 24 week . Each patient receive dose entire time he/she study . However , patient may receive different dose patient depend upon enter study . When study begin , first three patient receive dose 400 mg/m2 . After observed 2 week , side effect occur tolerable , another three patient enter study high dose . The increase dose may continue new patient group side effect reach point tolerate . At point high dos try patient allow enter one two low dos side effect tolerate . Up 55 patient enter study 8 research center United States . Study duration approximately 27 week 8 treatment cycle ( One treatment cycle last 3 week begin Day 1 infusion AQ4N . ) The following procedure complete time screen throughout study : review medical cancer history , previous cancer treatment , current medication , complete physical exam , blood ( 4 6 teaspoon ) urine test . Two additional test evaluate heart , electrocardiogram ( ECG ) multiple gated acquisition assessment ( MUGA ) perform . Cancer progression monitor computed tomography scan ( CT scan ) bone marrow biopsy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Diagnosis NonHodgkin 's Lymphoma , Chronic Lymphocytic Leukemia , Small Lymphocytic Leukemia Tumor specimen available evaluation ( please provide 10 unstained slide ) Relapse receive primary treatment least one salvage therapy Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 2 Laboratory test measurement Females childbearing potential must negative pregnancy test result within 3 day prior first dose must agree use effective contraceptive method course study 6 month follow last dose study drug . Older 18 year age Available periodic blood sample Certain cardiac problem Previous donor stem cell transplant Known HIV , Hepatitis B , Hepatitis C infection Previous chemotherapy , radiation investigational drug treatment within 4 week first plan dose study drug Major surgery within four week first plan dose study drug Any active viral , bacterial , fungal infection within four week first plan dose study drug Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Small Lymphocytic Leukemia</keyword>
</DOC>